Genetics may predict GLP‑1 results

Glucagon-like peptide 1 drugs work by imitating a gut hormone your body already makes after you eat, which helps you feel full sooner and slows how fast food leaves the stomach. Drugs in this family include semaglutide and tirzepatide, which are now widely used for obesity treatment. (nature.com) The strange part is how uneven the results are. In 23andMe’s April 8, 2026 announcement, the company said some people on these drugs lose less than 5% of body weight while others lose more than 20%, and some get nausea or vomiting while others do not. (23andme.com) Genes are the body’s instruction manual, and small spelling changes in that manual can change how a drug target behaves. A Nature paper published April 8, 2026 tested whether those small changes could explain part of the gap between people who do very well on these medicines and people who do not. (nature.com) The researchers used a genome-wide association study, which is a giant comparison across the genome to see which DNA differences show up more often in people with a shared outcome. They analyzed self-reported weight loss and side effects from 27,885 people who had used a glucagon-like peptide 1 receptor agonist. (nature.com) One signal showed up in GLP1R, the gene that helps build the receptor these drugs are meant to hit like a key fitting a lock. The paper found a missense variant in GLP1R associated with greater efficacy, with about 0.76 kilograms of extra weight loss expected per copy of the effect allele. (nature.com) A second set of signals showed up around nausea and vomiting rather than weight loss. The study found links involving both GLP1R and GIPR, and the GIPR signal appeared only in people using tirzepatide, which acts on both glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide pathways. (nature.com) That drug-specific detail matters because semaglutide and tirzepatide are not identical medicines. Nature described semaglutide as a glucagon-like peptide 1 receptor agonist, while tirzepatide was described as a dual glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptor agonist, so a gene tied to the second pathway would not be expected to affect both drugs the same way. (nature.com) 23andMe says it has already turned the research into a consumer-facing report called “GLP-1 Medications Weight Loss and Nausea,” available through its Total Health service. The company says that service includes clinician guidance and that the report is intended for supervised clinical use rather than stand-alone self-diagnosis. (23andme.com) The company also says its broader model combines genetic findings with demographic and clinical factors instead of pretending DNA is the whole story. In other words, the report is trying to estimate odds, not promise that one gene change guarantees a certain amount of weight loss or a certain side effect. (23andme.com) The real test comes next, outside a research database and inside ordinary clinics. The Nature paper says the findings “lay the foundation” for precision medicine in obesity, which means matching treatment more closely to the patient, but foundation is not the same thing as standard practice. (nature.com) If the result holds up in more real-world validation, prescribing these drugs could start to look less like trial and error. A doctor could eventually use genetics the way a mechanic uses a diagnostic scan: not to decide everything, but to spot who is more likely to benefit, who may need closer monitoring, and which drug may be a rougher ride. (nature.com)